Prognostic histological and immune markers of renal cell carcinoma.
Recent development on the fields of molecular genetics and immunology of human renal cell carcinoma (RCC) have resulted in more successful treatment of advanced and metastatic RCCs. Re-evaluation of the prognostic/predictive data aim the initial tumor staging of RCC patients to achieve better patient selection for immune and gene therapy. 125 RCC patients diagnosed according to the Heidelberg histological classification, graded, Robson staged, immune treated (Interferon-a a+ Vinblastine or Broncho-Waxom/Decaris) were followed-up clinically for 36 months. Tumor immunity markers by immunohistochemistry of tumor infiltrating lymphocytes (TIL) were detected by immunoperoxidase methods using monoclonal antibodies. Tumoral immune complexes (TIC) were visualized by fluorescent polyclonal antibodies. Histologically oncocytomas defined a better (p<0.02) and sarcomatous RCCs a worse (p<0.01) follow-up prognosis. Basically, the metastatic status (related with the stage and grade) determined the clinical outcome (p<0.00002) of the RCC patients. Tumoral immune complexes (TIC) were weak positive, while tumor infiltrating lymphocytes (TIL) weak negative predictors of the succes of Broncho-Waxom/Decaris immune therapy. Molecular genetic based histological classification, grade, stage and metastatic status parameters together with some tumor immunity parameters (TIL, TIC) can predict the success of immunotherapy of RCC patients.
Magyarlaki
T
T
University of Pécs, Medical Faculty, Department of Clinical Biochemistry Ifjúság útja 13., Pécs, Hungary. kellerm@apacs.pote.hu
Buzogány
I
I
Kaiser
L
L
Sükösd
F
F
Döbrönte
R
R
Simon
B
B
Fazekas
A
A
Nagy
J
J
D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D002292:Carcinoma, Renal Cell / Q000737:chemistry* / Q000401:mortality / Q000628:therapy; D003131:Combined Modality Therapy; D018450:Disease Progression; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D007155:Immunologic Factors / Q000627:therapeutic use; D007167:Immunotherapy; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000737:chemistry* / Q000401:mortality / Q000628:therapy; D007978:Levamisole / Q000627:therapeutic use; D016246:Lymphocytes, Tumor-Infiltrating; D009363:Neoplasm Proteins / Q000032:analysis; D009367:Neoplasm Staging; D009392:Nephrectomy; D011379:Prognosis; D011994:Recombinant Proteins; D016896:Treatment Outcome; D014747:Vinblastine / Q000627:therapeutic use
D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; D007155:Immunologic Factors; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D009363:Neoplasm Proteins; D011994:Recombinant Proteins; D007978:Levamisole; D014747:Vinblastine